投稿注册咨询:400-008-5413 销售咨询:010-6029 9110、80259978
刘娜:Inhibition of HDAC6 blocks the development and progression of peritoneal fibrosis PPT讲座视频 The 8th Asia Pacific Chapter Meeting of International Society for Peritoneal Dialysis (APCM-ISPD 2017)
标题: Inhibition of HDAC6 blocks the development and progression of peritoneal fibrosis
讲者: 刘娜
单位: 上海市东方医院同济大学附属东方医院
播放: 1903
论文摘要: Peritoneal fibrosis is the primary cause for patients to drop out from peritoneal dialysis (PD). There is a report showing that activation of class I histone deactylases (HDACs) are correlated with development of peritoneal fibrosis. However, it remains unclear whether HDAC6, one of class II HDAC isoforms, could play a role in peritoneal fibrosis. In this study, we investigated the effect of Tubastatin A (TA), a highly selective HDAC6 inhibitor, on the initiation and development of peritoneal fibrosis. In a mouse model of peritoneal fibrosis induced by daily intraperitoneal administration of 4.25% peritoneal dialysis solution for 28 days, increased collagen deposition and the thickening of the submesothelial region were evident. Administration with TA attenuated the development and progression of peritoneal fibrosis. This was accompanied by induction of histone H3 acetylation, inhibition of transforming growth factor (TGF) receptor expression and Smad-3 phosphorylation, as well as preservation of Smad-7 expression. TA treatment also inhibited phosphorylation of epidermal growth factor receptor (EGFR), and nuclear factor (NF)-κB and signal transducer and activator of transcription 3. Furthermore, HDAC6 inhibition suppressed a variety of inflammatory cytokines, reduced the infiltration of macrophages to the injured peritoneum, and inhibited peritoneal increase of CD31 (+) blood vessels and vascular endothelial growth factor (+) cells after high glucose injury. In human peritoneal mesothelial cells (HPMCs), we also observed that TA treatment dose-dependently suppressed TGF-b1-induced expression of α-SMA and collagen-I, as well as phosphorylation of Smad3. These results suggest that TA can block the progression of peritoneal fibrosis by upregulation of histone acetylation, and subsequently inhibition of multiple fibrogentic signaling pathway activation and inflammatory responses as well as blockade of angiogenesis. Thus, targeted inhibition of HDAC6 could be an effective and potential therapy to treat peritoneal fibrosis in human.

肾内科

上海市东方医院(同济大学附属东方医院)

刘娜,女,同济大学医学博士,美国布朗大学附属罗德岛医院肾内科访问学者,现任同济大学附属东方医院肾内科副主任,副主任医师,副教授,内科学博士生导师。主持三项国家自然基金,先后入选浦东新区卫生系统优秀青年医学人才、上海市浦江人才计划、上海市杰青医学人才培养计划;并获得浦东新区卫生系统医学人才培养优胜奖。目前为中国药理学会肾脏药理专业委员会全国委员,上海市浦东新区肾脏专委会委员,国家自然基金重点项目和面上项目评审专家。 ... 更多
该讲者其他视频
相关视频
该讲者其他论文

l 表观遗传学与腹膜纤维化

作者: 刘娜

单位: 上海市东方医院(同济大学附属东方医院)

来源: 中国生理学会肾脏专业委员会第六届学术年会

l IgA肾病临床与病理关联性分析

作者: 施映枫

单位: 上海市东方医院(同济大学附属东方医院)

来源: 中华医学会肾脏病学分会2017年学术年会

l

作者: 刘娜

单位: 上海市东方医院(同济大学附属东方医院)

来源: 中华医学会肾脏病学分会2016年血液净化论坛

l

作者: 庄守刚

单位: 上海市东方医院(同济大学附属东方医院)

来源: 中华医学会肾脏病学分会2016年血液净化论坛

相关论文
学术交流区 (0条留言)
最新留言
产品&服务
• 学会/协会管理系统
• 会务通学术会议服务平台
• 现场注册签到管理系统
• 会场幻灯传输转播系统
• 学术会议网络直播系统
• E-Poster电子壁报系统
• 企业数字助展服务
• 花生会议管理系统
帮助中心
• 功能更新
• 常见问题
关于我们
• 公司简介
• 版权声明
• 联系我们
微信扫描
美迪康官方微信
Copyright©2007-2017 MEDCON. All Rights Reserved.北京美迪康信息咨询有限公司 版权所有. 京ICP备11011505号-31 京公网安备 11011502002826号